Tyche Industries Ltd

Tyche Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 3 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 June 2026, providing investors with the latest insights into its performance and outlook.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 3 June 2026. This change reflects a nuanced improvement in the company’s financial trend and a shift in technical indicators, despite ongoing challenges in valuation and quality metrics.

Tyche Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in glucosamine hydrochloride and bulk drug intermediates, reported a challenging quarter for Q4 FY26 (January-March 2026) with net profit of ₹1.15 crores, marking a decline of 36.81% quarter-on-quarter and 22.34% year-on-year. Despite a strong 53.12% sequential revenue recovery to ₹16.20 crores, the company's operating profitability deteriorated sharply, with operating margins turning negative for the first time in recent quarters. The stock, currently trading at ₹138.00 with a market capitalisation of ₹136.00 crores, has gained 3.41% following the results announcement but faces mounting operational headwinds.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reported its quarterly results for March 2026, revealing a nuanced financial performance. While net sales reached a record high of ₹16.20 crores, profitability metrics continued to face headwinds, with operating margins contracting and net profit after tax declining sharply over the past six months.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026. This change is primarily driven by a shift in technical indicators, even as the company continues to grapple with deteriorating financial performance and expensive valuation metrics.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, stretched valuation metrics, and a bleak financial trend, signalling caution for investors amid ongoing underperformance relative to benchmarks.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. Despite a recent 5.12% decline in its share price to ₹135.30, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a nuanced change in price attractiveness relative to its historical averages and peer group. This article analyses these valuation changes in detail, placing them in the context of sector dynamics and broader market performance.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 11 May 2026. This change reflects a nuanced shift in the company’s technical outlook, valuation metrics, financial trends, and quality assessments amid a challenging operating environment and mixed market signals.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. This change comes amid a mixed performance relative to its peers and the broader market, raising questions about its price attractiveness and investment appeal.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift markedly, moving from an expensive to a very expensive rating. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture of price attractiveness relative to peers and historical benchmarks.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions and impacts the stock's price attractiveness relative to its historical averages and peer group, amid a challenging industry backdrop and mixed financial performance.